Insider trade

Chair exercised or converted 40K VRTX derivative securities

Traded Nov 14, 2025 · Filed Nov 17, 2025

Vertex PharmaceuticalsVRTX

40K
Shares · @ $86.52

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 14, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 17, 2025

ChairOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000875320-25-000234

Filed / recorded

Nov 17, 2025, 9:12 PM UTC

Added to OQRO

Oct 2, 2026, 12:29 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

VERTEX PHARMACEUTICALS INC / MA

Issuer CIK

875320

Ticker

VRTX

Reporting person

Jeffrey M Leiden

Relationship

Director, Officer

Officer title

Executive Chairman

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Nov 14, 2025

Transaction code

M

Shares / units

39,769

Price per share

$86.52

Acquired / disposed

Acquired (A)

Shares owned after

77,630

Ownership form

Direct

Amendment

No

Around the same time

Officer sold ~$3.16M of Vertex Pharmaceuticals

Scheduled in advance10mo ago

Officer sold ~$3.23M of Vertex Pharmaceuticals

Scheduled in advance10mo ago

Officer sold ~$2.02M of Vertex Pharmaceuticals

Scheduled in advance10mo ago